English 
Spanish 
3 min read
2 comments
New Nexus Pharmacêntica factory in Sorocaba will create 300 jobs, produce generic Ozempic and strengthen the pharmaceutical sector.
The City of Sorocaba (SP) made an important announcement about the installation of a new factory in the city's Technology Park. The new unit will be operated by Nexus Pharmacêutica, a pharmaceutical industry formed by the merger of three companies: LCA Farmacêutica, Stanley's Holding and Unikka Pharma.
Factory construction and investments
The new factory will occupy an initial area of 2 thousand square meters in the Technology Park, with an initial investment of R$ 20 million.
The total construction of the unit is expected to be completed within 24 months, with an additional investment of R$40 million, expanding the area to 6 thousand square meters.
- Turquoise hydrogen emerges as a game changer promising to revolutionize industry and accelerate energy transition
- Vale da Celulose: Mato Grosso do Sul will receive R$75 billion in investments in the cellulose sector, leading the industrial revolution in Brazil with 75% of the resources injected into the state
- With an investment of R$ 1,2 BILLION and the creation of more than 1000 jobs, Raízen begins construction of an E2G ethanol plant
- China takes another step towards its plan for global dominance by investing US$600 million in a megaproject that resurrects the Silk Road in the Taklamakan desert
The works should begin this year, with the technical project already ready, as reported by Lucas Gasparini, partner at LCA Farmacêutica.
The installation of the new pharmaceutical industry promises to create approximately 300 direct and indirect jobs. To meet the demand for new professionals, the city of Sorocaba intends to offer professional training courses.
This aims to prepare workers for the various areas needed in the factory and ensure that the local population benefits from the new employment opportunities.
Production of generic Ozempic and other medicines
One of the main products of the new factory It will be the generic version of Ozempic, a medicine currently manufactured by the Danish company Novo Nordisk, which holds the patent until 2026.
After the patent exclusivity period ends, Nexus Pharmacêntica will begin producing the generic, with an expected supply price of R$400.
In addition to Ozempic, the pharmaceutical industry plans to manufacture around 250 medicines, including dipyrone, antidepressants, antibiotics and creams.
These medicines will be distributed to both the Unified Health System (SUS) and pharmacy chains. The factory will not only produce the medicines, but will also be responsible for their sale and distribution from Sorocaba.
Impact on the local and regional economy
The arrival of Nexus Pharmacêntica in Sorocaba represents a significant economic boost for the region.
With the construction of the new factory, the city not only benefits from job creation, but also positions itself as an important hub in the pharmaceutical sector.
This development can attract other investments and companies to the Technology Park, promoting an environment of innovation and economic growth.
Furthermore, the continued investment in expanding the factory demonstrates the company's commitment to expanding and strengthening the local economy.
The production of generic Ozempic and the provision of a wide range of medicines aim to improve access to healthcare for the population.
By making essential medicines available at more affordable prices, the new factory will contribute to strengthening the Unified Health System (SUS) and help meet the needs of various social groups.
The presence of Nexus Pharmacêntica in Sorocaba reinforces the importance of having a robust pharmaceutical industry committed to public health and accessibility of treatments.
Partnerships and community collaboration in the factory
In addition to the economic and social benefits, the installation of Nexus Pharmacêntica in Sorocaba also opens space for partnerships and collaborations with local and regional institutions.
A company intends to work together with universities and research centers to promote innovations in the pharmaceutical field and develop new products.
This type of collaboration can generate research and development opportunities, as well as foster education and technological advancement in the region.
Integration with the local academic and scientific community will not only strengthen the factory's innovation capacity, but also contribute to the development of the pharmaceutical sector as a whole.
